Abstract:Background: Metabolic syndrome (MetS) is a chronic disorder featuring overweight/obesity, high blood pressure, and dysfunction of lipid and carbohydrate metabolism. Microbiome-modulating probiotics, prebiotics, synbiotics and fecal microbiota transplant (FMT) are promising adjunct therapies for improving parameters of glucose homeostasis and insulinemia. Methods: We conducted a comprehensive systematic review, meta-analyses, and meta-regressions to investigate the effect of the abovementioned microbiome therapies on various biomarkers after screening clinical trials published through April 2023. We pooled data using random effects meta-analyses, reporting them as mean differences (MDs) with 95 % confidence intervals (CIs), and conducting univariate linear model meta-regressions. Results: Data from 21 trial comparisons across 19 studies (n = 911) revealed that, compared to placebo/control, microbiome-modulating therapies were associated with statistically significant changes in fasting plasma glucose (MD: 4.03 mg/dL [95%CI: 6.93; -1.13]; p effect = 0.006, I2 = 89.8 %), and fasting insulin (MD: 2.56 μU/mL [95%CI: 4.28; -0.84]; p effect = 0.004, I2 = 87.9 %), but not insulin resistance or sensitivity indices and HbA1c. Age, baseline BMI, baseline biomarker value, pro/synbiotic dosage, trial duration, nutraceutical type, and WHO region were factors affecting the efficacy of these interventions at producing changes in biomarkers, signaling the potential role of personalized precision medicine adjunct therapy for deranged glucose homeostasis in patients with MetS. Nevertheless, presence of heterogeneity calls for further investigation before their clinical application. Conclusions: Probiotics, prebiotics, synbiotics and FMT supplementation improved fasting glucose and insulin in patients with MetS. Further large-scale and high-quality trials are required before potential clinical applications.

Dietary Strategies for Management of Metabolic Syndrome: Role of Gut Microbiota Metabolites

Gut microbiota-derived metabolites: implications for metabolic syndrome and therapeutic interventions

Harnessing the Power of the Gut Microbiome: A Review of Supplementation Therapies for Metabolic Syndrome

Gut Microbiota and Metabolic Syndrome: Relationships and Opportunities for New Therapeutic Strategies

Dietary Strategies Implicated in the Prevention and Treatment of Metabolic Syndrome

Pivotal Roles of Chronic Inflammation and Gut Microbiota

Probiotics and postbiotics: focus on metabolic syndrome

Gut Microbiota Disorders and Metabolic Syndrome: Tales of a Crosstalk Process

Advances in Gut Microbiota-Targeted Therapeutics for Metabolic Syndrome

Comprehensive Strategies for Metabolic Syndrome: How Nutrition, Dietary Polyphenols, Physical Activity, and Lifestyle Modifications Address Diabesity, Cardiovascular Diseases, and Neurodegenerative Conditions

Biomolecular Actions by Intestinal Endotoxemia in Metabolic Syndrome

The gut microbial community in metabolic syndrome patients is modified by diet

Role of the intestine and its gut microbiota in metabolic syndrome and obesity

The role of gut microbiota in the development of metabolic syndrome

Gut Microbiota-Based Translational Biomarkers to Prevent Metabolic Syndrome Via Nutritional Modulation

Food Emulsifiers and Metabolic Syndrome: The Role of the Gut Microbiota

Diet and metabolic syndrome: a narrative review

Gut Microbiota and Cardiovascular Disease: Evidence on the Metabolic and Inflammatory Background of a Complex Relationship

Interplay between diet, the gut microbiome, and atherosclerosis: Role of dysbiosis and microbial metabolites on inflammation and disordered lipid metabolism

The effect of microbiome-modulating therapeutics on glucose homeostasis in metabolic syndrome: A systematic review, meta-analysis, and meta-regression of clinical trials

Nutraceutical approaches to metabolic syndrome